{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:49:41Z","timestamp":1775461781101,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04843-z","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:47:22Z","timestamp":1764233242000},"page":"7689-7699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of rivaroxaban in the management of coronary artery disease: an overview of five landmark clinical trials"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4824-7673","authenticated-orcid":false,"given":"Anshu","family":"Thakur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-0986","authenticated-orcid":false,"given":"Mehul R.","family":"Chorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"4843_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008465","volume":"13","author":"BQ Abadie","year":"2020","unstructured":"Abadie BQ, Cannon CP, Cavender MA (2020) Novel oral anticoagulants following percutaneous coronary intervention. Circ Cardiovasc Interv 13:e008465. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.008465","journal-title":"Circ Cardiovasc Interv"},{"key":"4843_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/14740338.2025.2462652","volume":"24","author":"T Abdul-Rahman","year":"2025","unstructured":"Abdul-Rahman T, Roy P, Herrera-Calder\u00f3n RE et al (2025) Rivaroxaban to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease: a narrative review. Expert Opin Drug Saf 24:261\u2013271. https:\/\/doi.org\/10.1080\/14740338.2025.2462652","journal-title":"Expert Opin Drug Saf"},{"key":"4843_CR3","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","volume":"71","author":"SS Anand","year":"2018","unstructured":"Anand SS, Caron F, Eikelboom JW et al (2018) Major adverse limb events and mortality in patients with peripheral artery disease. J Am Coll Cardiol 71:2306\u20132315. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.008","journal-title":"J Am Coll Cardiol"},{"key":"4843_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/pin.12921","volume":"70","author":"Y Asada","year":"2020","unstructured":"Asada Y, Yamashita A, Sato Y, Hatakeyama K (2020) Pathophysiology of atherothrombosis: mechanisms of thrombus formation on disrupted atherosclerotic plaques. Pathol Int 70:309\u2013322. https:\/\/doi.org\/10.1111\/pin.12921","journal-title":"Pathol Int"},{"key":"4843_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/CIRCULATIONAHA.119.044598","volume":"141","author":"KR Bainey","year":"2020","unstructured":"Bainey KR, Welsh RC, Connolly SJ et al (2020) Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS-PCI). Circulation 141:1141\u20131151. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044598","journal-title":"Circulation"},{"key":"4843_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jama.295.2.180","volume":"295","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295:180. https:\/\/doi.org\/10.1001\/jama.295.2.180","journal-title":"JAMA"},{"key":"4843_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM et al (2010) Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304:1350. https:\/\/doi.org\/10.1001\/jama.2010.1322","journal-title":"JAMA"},{"key":"4843_CR8","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.046448","volume":"141","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Eikelboom JW, Connolly SJ et al (2020) Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial. Circulation 141:1841\u20131854. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046448","journal-title":"Circulation"},{"key":"4843_CR9","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Bauersachs RM, Anand SS et al (2020) Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 382:1994\u20132004. https:\/\/doi.org\/10.1056\/NEJMoa2000052","journal-title":"N Engl J Med"},{"key":"4843_CR10","first-page":"376","volume":"97","author":"MM Braun","year":"2018","unstructured":"Braun MM, Stevens WA, Barstow CH (2018) Stable coronary artery disease: treatment. Am Fam Physician 97:376\u2013384","journal-title":"Am Fam Physician"},{"key":"4843_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13071956","volume":"13","author":"A Breitenstein","year":"2024","unstructured":"Breitenstein A, Gay A, Vogtl\u00e4nder K et al (2024) The net clinical outcome of dual-pathway inhibition in clinical practice: the \u201cXarelto plus acetylsalicylic acid: treatment patterns and outcomes in patients with atherosclerosis\u201d registry. J Clin Med 13:1956. https:\/\/doi.org\/10.3390\/jcm13071956","journal-title":"J Clin Med"},{"key":"4843_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/MCA.0000000000000031","volume":"24","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee S, Sharma A, Uchino K et al (2013) Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis 24:628\u2013635. https:\/\/doi.org\/10.1097\/MCA.0000000000000031","journal-title":"Coron Artery Dis"},{"key":"4843_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/ATVBAHA.121.317171","volume":"42","author":"R Choxi","year":"2022","unstructured":"Choxi R, Kapoor K, Mackman N, Jovin IS (2022) Direct oral anticoagulants and coronary artery disease. Arterioscler Thromb Vasc Biol 42:553\u2013564. https:\/\/doi.org\/10.1161\/ATVBAHA.121.317171","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4843_CR14","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2022.0277","author":"T Doenst","year":"2022","unstructured":"Doenst T, Thiele H, Haasenritter J et al (2022) The treatment of coronary artery disease\u2014current status six decades after the first bypass operation. Dtsch \u00c4rztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2022.0277","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"4843_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4103\/jpcs.jpcs_28_25","volume":"11","author":"P Dua","year":"2025","unstructured":"Dua P, Reeta KH (2025) An evidence based, population tailored, economical risk prediction tool for coronary artery disease: a need of the hour. J Pract Cardiovasc Sci 11:191\u2013192. https:\/\/doi.org\/10.4103\/jpcs.jpcs_28_25","journal-title":"J Pract Cardiovasc Sci"},{"key":"4843_CR16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319\u20131330. https:\/\/doi.org\/10.1056\/NEJMoa1709118","journal-title":"N Engl J Med"},{"key":"4843_CR17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/ehjcvp\/pvac023","volume":"8","author":"JW Eikelboom","year":"2022","unstructured":"Eikelboom JW, Bosch J, Connolly SJ et al (2022) Long-term treatment with the combination of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: outcomes during the open label extension of the COMPASS trial. Eur Heart J Cardiovasc Pharmacother 8:786\u2013795. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4843_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.avsg.2024.04.005","volume":"106","author":"G Elzawy","year":"2024","unstructured":"Elzawy G, Chan J, Eisenberg N, Roche-Nagle G (2024) Following the COMPASS: antithrombotic prescription trends in patients with symptomatic peripheral arterial disease following revascularization. Ann Vasc Surg 106:341\u2013349. https:\/\/doi.org\/10.1016\/j.avsg.2024.04.005","journal-title":"Ann Vasc Surg"},{"key":"4843_CR19","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","volume":"14","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M et al (2022) Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics 14:1120. https:\/\/doi.org\/10.3390\/pharmaceutics14061120","journal-title":"Pharmaceutics"},{"key":"4843_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ehjcvp\/pvac028","volume":"8","author":"KAA Fox","year":"2022","unstructured":"Fox KAA, Aboyans V, Debus ES et al (2022) Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: the XATOA registry. Eur Heart J Cardiovasc Pharmacother 8:825\u2013836. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac028","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4843_CR21","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.jcin.2024.08.022","volume":"17","author":"M Galli","year":"2024","unstructured":"Galli M, Gragnano F, Berteotti M et al (2024) Antithrombotic therapy in high bleeding risk, part I. JACC Cardiovasc Interv 17:2197\u20132215. https:\/\/doi.org\/10.1016\/j.jcin.2024.08.022","journal-title":"JACC Cardiovasc Interv"},{"key":"4843_CR22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","volume":"147","author":"A Greco","year":"2023","unstructured":"Greco A, Laudani C, Spagnolo M et al (2023) Pharmacology and clinical development of factor XI inhibitors. Circulation 147:897\u2013913. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062353","journal-title":"Circulation"},{"key":"4843_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.102017","volume":"49","author":"A Hajra","year":"2024","unstructured":"Hajra A, Ujjawal A, Ghalib N et al (2024) Expanding indications of nonvitamin K oral anticoagulants beyond nonvalvular atrial fibrillation and venous thromboembolism: a review of emerging clinical evidence. Curr Probl Cardiol 49:102017. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102017","journal-title":"Curr Probl Cardiol"},{"issue":"8","key":"4843_CR24","doi-asserted-by":"publisher","first-page":"E844","DOI":"10.21037\/jtd.2016.07.45","volume":"8","author":"G Helft","year":"2016","unstructured":"Helft G (2016) Dual antiplatelet therapy duration after drug-eluting stents: how long? J Thorac Dis 8(8):E844\u2013E846. https:\/\/doi.org\/10.21037\/jtd.2016.07.45","journal-title":"J Thorac Dis"},{"key":"4843_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","volume":"145","author":"IL Holster","year":"2013","unstructured":"Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL (2013) New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 145:105-112.e15. https:\/\/doi.org\/10.1053\/j.gastro.2013.02.041","journal-title":"Gastroenterology"},{"key":"4843_CR26","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.jvs.2025.03.394","volume":"82","author":"A Hundito","year":"2025","unstructured":"Hundito A, Wells N, Tuttle M et al (2025) The incidence and significance of delayed bleeding events after lower extremity revascularization in patients with advanced peripheral arterial disease. J Vasc Surg 82:969-977.e5. https:\/\/doi.org\/10.1016\/j.jvs.2025.03.394","journal-title":"J Vasc Surg"},{"key":"4843_CR27","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S75024","volume":"11","author":"S Husted","year":"2015","unstructured":"Husted S (2015) Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients. Ther Clin Risk Manag 263. https:\/\/doi.org\/10.2147\/TCRM.S75024","journal-title":"Ther Clin Risk Manag"},{"key":"4843_CR28","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.4244\/EIJ-D-24-00673","volume":"21","author":"D Kang","year":"2025","unstructured":"Kang D, Choi KH, Park H et al (2025) Effects of proton pump inhibitors on gastrointestinal bleeding and cardiovascular outcomes in myocardial infarction patients treated with DAPT. EuroIntervention 21:e229\u2013e239. https:\/\/doi.org\/10.4244\/EIJ-D-24-00673","journal-title":"EuroIntervention"},{"key":"4843_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"DJ Kumbhani","year":"2021","unstructured":"Kumbhani DJ, Cannon CP, Beavers CJ et al (2021) 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease. J Am Coll Cardiol 77:629\u2013658. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.011","journal-title":"J Am Coll Cardiol"},{"key":"4843_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40256-023-00620-6","volume":"24","author":"A Lamy","year":"2024","unstructured":"Lamy A, Eikelboom J, Tong W et al (2024) The cost-effectiveness of rivaroxaban plus aspirin compared with aspirin alone in the COMPASS trial: a US perspective. Am J Cardiovasc Drugs 24:117\u2013127. https:\/\/doi.org\/10.1007\/s40256-023-00620-6","journal-title":"Am J Cardiovasc Drugs"},{"key":"4843_CR31","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.3892\/etm.2020.8713","volume":"20","author":"CL Laslo","year":"2020","unstructured":"Laslo CL, Bacalbasa N, Stanescu AMA et al (2020) New oral anticoagulants - possible extension to other indications (Review). Exp Ther Med 20:2401\u20132405. https:\/\/doi.org\/10.3892\/etm.2020.8713","journal-title":"Exp Ther Med"},{"key":"4843_CR32","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S72268","volume":"10","author":"Y-J Lee","year":"2014","unstructured":"Lee Y-J (2014) Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients. Ther Clin Risk Manag 841. https:\/\/doi.org\/10.2147\/TCRM.S72268","journal-title":"Ther Clin Risk Manag"},{"key":"4843_CR33","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","volume":"133","author":"CC Low Wang","year":"2016","unstructured":"Low Wang CC, Hess CN, Hiatt WR, Goldfine AB (2016) Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation 133:2459\u20132502. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.022194","journal-title":"Circulation"},{"key":"4843_CR34","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.jcin.2021.07.045","volume":"14","author":"T Matoba","year":"2021","unstructured":"Matoba T, Yasuda S, Kaikita K et al (2021) Rivaroxaban monotherapy in patients with atrial fibrillation after coronary stenting. JACC Cardiovasc Interv 14:2330\u20132340. https:\/\/doi.org\/10.1016\/j.jcin.2021.07.045","journal-title":"JACC Cardiovasc Interv"},{"key":"4843_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1112277","journal-title":"N Engl J Med"},{"key":"4843_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1053\/j.gastro.2019.04.041","volume":"157","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi P, Eikelboom JW, Bosch J et al (2019) Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 157:403-412.e5. https:\/\/doi.org\/10.1053\/j.gastro.2019.04.041","journal-title":"Gastroenterology"},{"key":"4843_CR37","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51089","volume":"15","author":"BS Mody","year":"2023","unstructured":"Mody BS, Wadhwa M, Roy R, Echila S (2023) Current evidence and expert opinion on thromboprophylaxis after total knee and hip replacement. Cureus 15:e51089. https:\/\/doi.org\/10.7759\/cureus.51089","journal-title":"Cureus"},{"key":"4843_CR38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/2040620717733691","volume":"8","author":"JY Moon","year":"2017","unstructured":"Moon JY, Nagaraju D, Franchi F et al (2017) The role of oral anticoagulant therapy in patients with acute coronary syndrome. Ther Adv Hematol 8:353\u2013366. https:\/\/doi.org\/10.1177\/2040620717733691","journal-title":"Ther Adv Hematol"},{"key":"4843_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7636104","volume":"2020","author":"MTP Mujer","year":"2020","unstructured":"Mujer MTP, Rai MP, Atti V et al (2020) An update on the reversal of non-vitamin K antagonist oral anticoagulants. Adv Hematol 2020:7636104. https:\/\/doi.org\/10.1155\/2020\/7636104","journal-title":"Adv Hematol"},{"key":"4843_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac779.052","volume":"44","author":"T Noda","year":"2023","unstructured":"Noda T, Nochioka K, Kaikita K et al (2023) Antithrombotic monotherapy for stable coronary artery disease and atrial fibrillation patients with and without prior coronary artery revascularization: insights from the AFIRE trial. Eur Heart J 44:ehac779.052. https:\/\/doi.org\/10.1093\/eurheartj\/ehac779.052","journal-title":"Eur Heart J"},{"key":"4843_CR41","unstructured":"Olvera Lopez E, Ballard BD, Jan A. (2025) Cardiovascular disease. [Updated 2023 Aug 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;"},{"key":"4843_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-020-00114-1","volume":"6","author":"C Paul","year":"2020","unstructured":"Paul C, Baby M, Anthraper AR, K K (2020) NOACs: an emerging class of oral anticoagulants-a review article. Future J Pharm Sci 6:95. https:\/\/doi.org\/10.1186\/s43094-020-00114-1","journal-title":"Future J Pharm Sci"},{"key":"4843_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","volume":"3","author":"B Scally","year":"2018","unstructured":"Scally B, Emberson JR, Spata E et al (2018) Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 3:231\u2013241. https:\/\/doi.org\/10.1016\/S2468-1253(18)30037-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4843_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","volume":"23","author":"M Sharma","year":"2024","unstructured":"Sharma M, Molina CA, Toyoda K et al (2024) Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 23:46\u201359. https:\/\/doi.org\/10.1016\/S1474-4422(23)00403-9","journal-title":"Lancet Neurol"},{"key":"4843_CR45","unstructured":"Singh R, Emmady PD. Rivaroxaban. [Updated 2023 Apr 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557502\/. Accessed 15\u00a0Jul 2025"},{"key":"4843_CR46","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/jpm12071180","volume":"12","author":"A Sofogianni","year":"2022","unstructured":"Sofogianni A, Stalikas N, Antza C, Tziomalos K (2022) Cardiovascular risk prediction models and scores in the era of personalized medicine. J Pers Med 12:1180. https:\/\/doi.org\/10.3390\/jpm12071180","journal-title":"J Pers Med"},{"key":"4843_CR47","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1161\/CIRCULATIONAHA.121.057577","volume":"144","author":"M S\u00f8gaard","year":"2021","unstructured":"S\u00f8gaard M, Eldrup N, Nielsen PB (2021) Navigating the passage for better understanding and prognosis for acute limb ischemia after lower-extremity revascularization. Circulation 144:1842\u20131844. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057577","journal-title":"Circulation"},{"key":"4843_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1197","volume":"297","author":"PhG Steg","year":"2007","unstructured":"Steg PhG, Bhatt DL, Wilson PWF et al (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297:1197. https:\/\/doi.org\/10.1001\/jama.297.11.1197","journal-title":"JAMA"},{"key":"4843_CR49","doi-asserted-by":"publisher","unstructured":"Upadhyaya SGN, Sharma V, Connolly D (2020) Combining rivaroxaban with aspirin in stable atherosclerotic vascular disease: clinical evidence from the COMPASS study. Br J Cardiol 27(suppl 1):515-520. https:\/\/doi.org\/10.5837\/bjc2020.s04","DOI":"10.5837\/bjc2020.s04"},{"key":"4843_CR50","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV et al (2022) The global burden of cardiovascular diseases and risk. J Am Coll Cardiol 80:2361\u20132371. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.005","journal-title":"J Am Coll Cardiol"},{"key":"4843_CR51","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV et al (2023) 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation 148:1168. https:\/\/doi.org\/10.1161\/CIR.0000000000001168","journal-title":"Circulation"},{"key":"4843_CR52","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC et al (2024) 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 45:3415\u20133537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177","journal-title":"Eur Heart J"},{"key":"4843_CR53","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41401-024-01305-9","volume":"45","author":"W-Z Wang","year":"2024","unstructured":"Wang W-Z, Liu C, Luo J-Q et al (2024) A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis. Acta Pharmacol Sin 45:2119\u20132133. https:\/\/doi.org\/10.1038\/s41401-024-01305-9","journal-title":"Acta Pharmacol Sin"},{"key":"4843_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-025-02289-2","author":"X Wang","year":"2025","unstructured":"Wang X, Xie N, Zhang H et al (2025) Isoorientin ameliorates macrophage pyroptosis and atherogenesis by reducing KDM4A levels and promoting SKP1-Cullin1-F-box E3 ligase-mediated NLRP3 ubiquitination. Inflammation. https:\/\/doi.org\/10.1007\/s10753-025-02289-2","journal-title":"Inflammation"},{"key":"4843_CR55","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W et al (2018) 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J 39:3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"key":"4843_CR56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/clc.23514","volume":"44","author":"C Xie","year":"2021","unstructured":"Xie C, Hang Y, Zhu J et al (2021) Benefit and risk of adding rivaroxaban in patients with coronary artery disease: a systematic review and meta\u2010analysis. Clin Cardiol 44:20\u201326. https:\/\/doi.org\/10.1002\/clc.23514","journal-title":"Clin Cardiol"},{"key":"4843_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeae083","volume":"4","author":"F Xie","year":"2024","unstructured":"Xie F, Yan J, Eikelboom J et al (2024) Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Eur Heart J Open 4:oeae083. https:\/\/doi.org\/10.1093\/ehjopen\/oeae083","journal-title":"Eur Heart J Open"},{"key":"4843_CR58","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","volume":"381","author":"S Yasuda","year":"2019","unstructured":"Yasuda S, Kaikita K, Akao M et al (2019) Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 381:1103\u20131113. https:\/\/doi.org\/10.1056\/NEJMoa1904143","journal-title":"N Engl J Med"},{"key":"4843_CR59","first-page":"3","volume-title":"The ESC handbook on cardiovascular pharmacotherapy","author":"R Zweiker","year":"2019","unstructured":"Zweiker R, Perl S (2019) Hypertension. In: Kaski JC, Kjeldsen KP (eds) The ESC handbook on cardiovascular pharmacotherapy, 2nd edn. Oxford University Press, Oxford, pp 3\u201332","edition":"2"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04843-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04843-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04843-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:52:49Z","timestamp":1775458369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04843-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4843"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04843-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this is a review study and did not use preclinical (animal) or clinical (human) level data, no Ethics Committee approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent for publication was obtained from the co-authors involved in the preparation of the review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the authors declare that no generative AI or AI-assisted technologies have been utilized while drafting this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of use of generative AI or AI-assisted technologies"}}]}}